Short-term metabolic change is associated with improvement in measures of diabetic neuropathy: A 1-year placebo cohort analysis

Diabetic Medicine

Volumn 27, Issue 11, 2010, Pages 1271-1279

  Perkins, B A ^a   Dholasania, A ^a   Buchanan, R A ^b   Bril, V ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Dainippon Sumitomo Pharma Ltd   (United States)

Author keywords

Clinical risk factors; Diabetic neuropathy; Diabetic sensorimotor polyneuropathy; Nerve conduction studies; Triglyceride level

Indexed keywords

HEMOGLOBIN A1C; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIAN NERVE; METABOLIC DISORDER; MULTICENTER STUDY; NERVE FUNCTION; RANDOMIZED CONTROLLED TRIAL; SENSORIMOTOR NEUROPATHY; SENSORY NERVE CONDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; NEURAL CONDUCTION; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGLYCERIDES; YOUNG ADULT;

EID: 77958586755     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03110.x     Document Type: Article

References (29)

1. Tesfaye S, Chaturvedi N, Eaton SEM, Ward JD, Manes C, Ionescu-Tirgoviste C et al.; EURODIAB Prospective Complications Study Group Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-350.
2. Vinik AI, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB, Colen LB. Diabetic neuropathies. Diabetes Care 1992; 15: 1926-1975.
3. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 89-94.
4. Coppini DV, Spruce MC, Thomas P, Masding MG. Established diabetic neuropathy seems irreversible despite improvements in metabolic and vascular risk markers-a retrospective case-control study in a hospital patient cohort. Diabet Med 2006; 23: 1016-1020.
5. Negrin P, Zara G. Conduction studies as prognostic parameters in the natural history of diabetic neuropathy: a long-term follow-up of 114 patients. Electromyogr Clin Neurophysiol 1995; 35: 341-350.
6. Akbari CM, Gibbons GW, Habershaw GM, LoGerfo FW, Veves A. The effect of arterial reconstruction on the natural history of diabetic neuropathy. Arch Surg 1997; 132: 148-152.
7. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
8. Allen RDM, Al-Harbi IS, Morris JG, Clouston PD, O'Connell PJ, Chapman JR et al. Diabetic neuropathy after pancreas transplantation: determinants of recovery. Transplantation 1997; 63: 830-838.
9. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA et al., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010; 33: 1090-1096.
10. Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 2010; 10: 276-282.
11. Tesfaye S, Tandan R, Bastyr EJ 3rd, Kles KA, Skljarevski V, Price KL. Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials. Diabetes Care 2007; 30: 2626-2632.
12. Bril V, Hirose T, Tomioka S, Buchanan R. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009; 32: 1256-1260.
13. Balducci S, Iacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications 2006; 20: 216-223.
14. Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989; 38: 1456-1461.
15. Anonymous. Report and recommendations of the San Antonio conference on diabetic neuropathy. Consensus statement. Diabetes 1988; 37: 1000-1004.
16. Anonymous. Executive summary: standards of medical care in diabetes-2010. Diabetes Care 2010; 33(Suppl 1): 4-10.
17. Bril V, Ellison R, Ngo M, Bergstrom B, Raynard D, Gin H, The Roche Neuropathy Study Group. Electrophysiological monitoring in clinical trials. Muscle Nerve 1998; 21: 1368-1373.
18. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002; 25: 2048-2052.
19. Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 2006; 29: 68-72.
20. Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III study). Alpha-Lipoic Acid in Diabetic Neuropathy (ALADIN III) study group. Diabetes Care 1999; 22: 1296-1301.
21. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29: 2365-2370.
22. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. J Am Med Assoc 1998; 280: 1831-136.
23. Wymer JP, Simpson J, Sen D, Bongardt S, Lacosamide SP742 Study Group. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain 2009; 25: 376-385.
24. Leonard KL. Is patient satisfaction sensitive to changes in the quality of care? An exploitation of the Hawthorne effect. J Health Econ 2008; 27: 444-459.
25. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
26. Ansquer JC, Foucher C, Aubonnet P, Le Malicot K. Fibrates and microvascular complications in diabetes-insight from the FIELD study. Curr Pharm Des 2009; 15: 537-552.
27. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009; 58: 1634-1640.
28. England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT et al.; American Academy of Neurology; American Association of Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64: 199-207.
29. Kennedy JM, Zochodne DW. Impaired peripheral nerve regeneration in diabetes mellitus. J Peripher Nerv Syst 2005; 10: 144-157.